Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: A literature-based meta-analysis of randomized studies

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 209-214

  Mörth, Charlott ^a   Valachis, Antonis ^a,b  

^a Cancercentrum   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Chemotherapy; Lung cancer; Meta analysis; Performance status

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; VINDESINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ADVANCED NON SMALL CELL LUNG CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901951940     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.015     Document Type: Review

References (24)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29.
2. Peter S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii56-vii64.
3. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., et al. 2011 focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
4. Lilenbaum R.C., Cashy J., Hensing T.A., Young S., Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 2006, 3:125-129.
5. Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001, 92:2639-2647.
6. Brundage M.D., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002, 122:1037-1057.
7. National Comprehensive Cancer Network Non-Small Cell Lung Cancer (Version 2.2014) 2014, [accessed 01.11.13], http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
8. Kosmidis P.A., Dimopoulos M.A., Syrigos K., Nicolaides C., Aravantinos G., Boukovinas I., et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007, 2:135-140.
9. Morabito A., Gebbia V., Di Maio M., Cinieri S., Vigano M.G., Bianco R., et al. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 2013, 81:77-83.
10. Reynolds C., Obasaju C., Schell M.J., Li X., Zheng Z., Boulware D., et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5808-5815.
11. Zukin M., Barrios C.H., Pereira J.R., Ribeiro R.A., Beato C.A., do Nascimento Y.N., et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013, 31:2849-2853.
12. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
13. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
14. Comella P., Frasci G., Carnicelli P., Massida B., Buzzi F., Filipelli G., et al. Gemcitabine with either paclitaxel or vinorelbine vs. paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004, 91:489-497.
15. Georgoulias V., Ardavanis A., Agelidou A., Agelidou M., Chandrinos V., Tsaroucha E., et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004, 22:2602-2609.
16. Hainsworth J.D., Spigel D.R., Farley C., Shipley D.L., Bearden J.D., Gandhi J., et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007, 110:2027-2034.
17. Le Chevalier T., Brisgand D., Soria J.C., Douillard J.Y., Pujol J.L., Ruffie P., et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001, 6(Suppl. 1):8-11.
18. Lilenbaum R.C., Herndon J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23:190-196.
19. Perrone F., Di Maio M., Gallo C., Gridelli C. Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 2004, 22:5018-5020.
20. Quoix E., Zalcman G., Oster J.P., Westeel V., Pichon E., Lavolé A., et al. Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088.
21. Sederholm C., Hillerdal G., Lamberg K., Kölbeck K., Dufmats M., Westberg R., et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005, 23:8380-8388.
22. Goffin J., Lacchetti C., Ellis P.M., Ung Y.C., Evans W.K., Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010, 5:260-274.
23. Ellison N.M. Palliative chemotherapy. Am J Hosp Palliat Care 1998, 15:93-103.
24. Stewart L.A., Parmar M.K.B. Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 1993, 341:418-422.